ORYZON Reports First Quarter 2016 Financial Results and Corporate Update


• The corporation revenue stands at €1.5 million and its equity reaches €27.8 million

• The company invested €1.2M in R&D

Oryzon Genomics (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, today reported financial results for the first quarter of 2016 and provided a corporate update on the Company’s recent developments. Oryzon has invested €1.2 million in research and development during the first quarter of 2016. The company’s equity increased by €14.6 million since the first quarter of 2015, reaching now a total of €27.8 million, €21.9 million of which comes from their own funds.

Click here to see the full Press Release